These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25506837)

  • 21. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia.
    Hartkamp A; Mulder AH; Rijkers GT; van Velzen-Blad H; Biesma DH
    Vaccine; 2001 Feb; 19(13-14):1671-7. PubMed ID: 11166890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
    Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
    Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
    Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia.
    Lindström V; Aittoniemi J; Salmenniemi U; Käyhty H; Huhtala H; Itälä-Remes M; Sinisalo M
    Hum Vaccin Immunother; 2018 Jun; 14(6):1471-1474. PubMed ID: 29420116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naïve and previously immunized adult patients with severe chronic kidney disease.
    Ulanova M; Huska B; Desbiens A; Gaultier GN; Domonkos V; McCready WG
    Vaccine; 2021 Jan; 39(4):699-710. PubMed ID: 33358702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].
    Duggan ST
    Drugs; 2010 Oct; 70(15):1973-86. PubMed ID: 20883054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to pneumococcal conjugate and polysaccharide vaccination in children with rheumatic disease.
    Jensen L; Christensen AE; Nielsen S; Pedersen FK; Rosthøj S; Jørgensen CS; Poulsen A
    Scand J Immunol; 2022 Feb; 95(2):e13118. PubMed ID: 34768311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy.
    Lee D; Jordan AI; Menges MA; Lazaryan A; Nishihori T; Gaballa SR; Shah BD; Pinilla-Ibarz J; Baluch A; Klinkova OV; Chavez JC; Jain MD; Locke FL
    Transplant Cell Ther; 2023 Apr; 29(4):277.e1-277.e9. PubMed ID: 35970303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumococcal 13-valent conjugate vaccine administration after inferior response to pneumococcal vaccine.
    Gupta R; Wong CS; Fonacier L
    Allergy Asthma Proc; 2017 Sep; 38(5):365-369. PubMed ID: 28814356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
    Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients.
    Oesterreich S; Lindemann M; Goldblatt D; Horn PA; Wilde B; Witzke O
    Vaccine; 2020 Apr; 38(17):3339-3350. PubMed ID: 32178906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
    Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
    Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years.
    Schwarz TF; Schmoele-Thoma B
    Vaccine; 2013 Jan; 31(2):291-4. PubMed ID: 23123107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
    Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
    Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
    Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
    Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia.
    Sinisalo M; Vilpo J; Itälä M; Väkeväinen M; Taurio J; Aittoniemi J
    Vaccine; 2007 Dec; 26(1):82-7. PubMed ID: 18053620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
    Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W
    Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.
    Chu K; Hu Y; Pan H; Wu J; Zhu D; Young MM; Luo L; Yi Z; Giardina PC; Gruber WC; Scott DA; Watson W
    Hum Vaccin Immunother; 2023 Aug; 19(2):2235926. PubMed ID: 37549923
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.